Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
Published: 03 December 2019
-
Views:
525
-
Likes:
7
-
Views:
525
-
Likes:
7
-
Up Next
-
10m 15s
-
5m 18sPart 5 DAPA-HF Trial
-
19m 18s
-
9m 54sPart 1 SGLT2 in HF Now and the Future Andrew JS Coats, Carolyn Lam
-
5m 9sPart 2 DAPA-HF Trial Design Rationale Felipe Martínez
Overview
The opportunity for cardiovascular disease prevention in patients with type 2 diabetes mellitus (T2DM) has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE) including sodium-glucose co-transporter-2 (SGLT2) demonstrating robust reductions in heart failure (HF). Although the exact mechanisms of cardiovascular (CV) benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects.
Recent trials — including the recently presented DAPA-HF — have provided further insight into the effectiveness of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in the absence of T2DM.
Learning Objectives
- Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data; differentiate the latest guideline updates for the treatment of T2D
- Consider comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF)
- Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF
- Assess the interrelationships linking diabetes, HF and CVD
- Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
- Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
More from this programme
Part 1
SGLT2 in HF Now and the Future
| 1 session | |
| SGLT2 in HF Now and the Future | Watch now |
Part 2
DAPA-HF Trial Design Rationale
| 1 session | |
| DAPA-HF Trial Design Rationale | Watch now |
Part 3
SGLT2 beyond diabetes
| 1 session | |
| SGLT2 beyond diabetes | Watch now |
Part 4
Guidelines, Recent Data & Future Practices
Part 5
DAPA-HF Trial
| 1 session | |
| DAPA-HF Trial | Watch now |
Part 6
Discussion with the DAPA-HF Trialist
Faculty Biographies
Lars H Lund
Associate Professor and Senior Consultant
Dr Lund's expertise is in HF big data and registry-based comparative outcomes studies and pragmatic trials. He is active in programs to improve utilisation of existing evidence-based interventions in heart failure with reduced ejection fraction, as well as in novel interventions.
Dr Lars Lund is an Editorial Board member of Cardiac Failure Review.